https://commons.ufh.ac.za/vital/access/manager/Index en-us 5 https://commons.ufh.ac.za/vital/access/manager/Repository/vital:3925 Wed 12 May 2021 23:30:20 SAST ]]> https://commons.ufh.ac.za/vital/access/manager/Repository/vital:3868 Thu 13 May 2021 02:18:46 SAST ]]> https://commons.ufh.ac.za/vital/access/manager/Repository/vital:65775 100 kDa through ultracentrifugation. Mass spectrometry also detected the most abundant peak for all fucoidans to be around 700 Da (m/z). Extracted fucoidans inhibited the activity of α-glucosidase more strongly than the commercial anti-diabetic agent acarbose but were inactive on α-amylase. Fucoidans were also shown to be mixed inhibitors of α-glucosidase. Compellingly, fucoidans synergistically inhibited α-glucosidase in combination with the anti-diabetic agent acarbose, highlighting prospects for combination therapy. Finally, fucoidans demonstrated some anti-proliferative characteristics on HCT116 cancer cells by inhibiting their ability to adhere to the tissue culture plate matrix. Furthermore, some fucoidan extracts inhibited the migration of HCT116 cancer cells from 3D spheroids. Some of our fucoidan extracts also inhibited HCT116 colony formation, demonstrating inhibition of long-term cell survival. The E. maxima water extract also inhibited glucose uptake by HCT116 cells, thereby influencing the glycolytic flux. In conclusion, biologically active fucoidans were successfully extracted from South African brown seaweeds. These fucoidans demonstrated anti-diabetic and anti-cancer properties, revealing their relevance as potential drugs for these diseases.]]> Thu 11 Jan 2024 18:08:05 SAST ]]>